Article in Genes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors at 3 institutions in 1 country.
Michela VitielloInstitute of Experimental Endocrinology and Oncology "G. Salvatore" (IEOS), National Research Council (CNR), 80131 Naples, Italy. michela.vitiello@gmail.com.
Giuseppe PalmaS.S.D. Sperimentazione Animale, Istituto Nazionale Tumori⁻IRCCS⁻Fondazione G. Pascale, 80131 Naples, Italy. g.palma@istitutotumori.na.it.
Mario MonacoFunctional Genomic Unit, Istituto Nazionale Tumori⁻IRCCS⁻Fondazione G. Pascale, 80131 Naples, Italy. m.monaco@istitutotumori.na.it.ORCID 0000-0001-8782-5061
Anna Maria BelloFunctional Genomic Unit, Istituto Nazionale Tumori⁻IRCCS⁻Fondazione G. Pascale, 80131 Naples, Italy. a.bello@istitutotumori.na.it.
Simona CamoraniInstitute of Experimental Endocrinology and Oncology "G. Salvatore" (IEOS), National Research Council (CNR), 80131 Naples, Italy. s.camorani@ieos.cnr.it.
Paola FrancescaInstitute of Experimental Endocrinology and Oncology "G. Salvatore" (IEOS), National Research Council (CNR), 80131 Naples, Italy. paolafrancesca1991@libero.it.
Domenica ReaS.S.D. Sperimentazione Animale, Istituto Nazionale Tumori⁻IRCCS⁻Fondazione G. Pascale, 80131 Naples, Italy. d.rea@istitutotumori.na.it.
Antonio BarbieriS.S.D. Sperimentazione Animale, Istituto Nazionale Tumori⁻IRCCS⁻Fondazione G. Pascale, 80131 Naples, Italy. a.barbieri@istitutotumori.na.it.
Gennaro ChiappettaFunctional Genomic Unit, Istituto Nazionale Tumori⁻IRCCS⁻Fondazione G. Pascale, 80131 Naples, Italy. g.chiappetta@istitutotumori.na.it.ORCID 0000-0002-7633-7932
Gabriella De VitaDepartment of Molecular Medicine and Medical Biotechnologies, University of Naples "Federico II", 80131 Naples, Italy. gdevita@unina.it.ORCID 0000-0002-7302-1174
Laura CerchiaInstitute of Experimental Endocrinology and Oncology "G. Salvatore" (IEOS), National Research Council (CNR), 80131 Naples, Italy. cerchia@unina.it.ORCID 0000-0002-7633-7932
Claudio ArraS.S.D. Sperimentazione Animale, Istituto Nazionale Tumori⁻IRCCS⁻Fondazione G. Pascale, 80131 Naples, Italy. c.arra@istitutotumori.na.it.ORCID 0000-0002-9171-1312
Monica FedeleInstitute of Experimental Endocrinology and Oncology "G. Salvatore" (IEOS), National Research Council (CNR), 80131 Naples, Italy. monica.fedele@cnr.it.ORCID 0000-0002-9171-1312
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITInstitute for Experimental Endocrinology and Oncology · ITUniversity of Naples Federico II · IT
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
PATZ1 is a transcriptional factor downregulated in thyroid cancer whose re-expression in thyroid cancer cells leads to a partial reversion of the malignant phenotype, including the capacity to proliferate, migrate, and undergo epithelial-to-mesenchymal transition. We have recently shown that
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.